Healthcare of Ontario Pension Plan Trust Fund Takes Position in Lumexa Imaging Holdings, Inc. $LMRI

Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) in the fourth quarter, HoldingsChannel reports. The fund acquired 1,500,000 shares of the company’s stock, valued at approximately $27,750,000.

Other hedge funds have also recently bought and sold shares of the company. Assetmark Inc. acquired a new stake in Lumexa Imaging during the 4th quarter valued at approximately $36,000. Barclays PLC acquired a new stake in Lumexa Imaging during the 4th quarter valued at approximately $133,000. Hudson Bay Capital Management LP acquired a new stake in Lumexa Imaging during the 4th quarter valued at approximately $237,000. TD Asset Management Inc acquired a new stake in Lumexa Imaging during the 4th quarter valued at approximately $1,264,000. Finally, Geode Capital Management LLC acquired a new stake in Lumexa Imaging during the 4th quarter valued at approximately $1,548,000.

Lumexa Imaging Stock Performance

NASDAQ:LMRI opened at $9.39 on Tuesday. The business’s 50 day moving average price is $8.85. Lumexa Imaging Holdings, Inc. has a 52 week low of $6.45 and a 52 week high of $19.45.

Insider Buying and Selling

In other news, Director Brett Brodnax bought 35,000 shares of Lumexa Imaging stock in a transaction on Tuesday, May 19th. The shares were bought at an average price of $7.25 per share, with a total value of $253,750.00. Following the acquisition, the director directly owned 62,027 shares in the company, valued at approximately $449,695.75. This represents a 129.50% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Weiss Ratings upgraded Lumexa Imaging from a “sell (e-)” rating to a “sell (e)” rating in a research note on Monday, June 1st. Barclays lowered their price objective on Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating for the company in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Lumexa Imaging has a consensus rating of “Moderate Buy” and an average target price of $16.00.

About Lumexa Imaging

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).